Evaluating Preventive Therapy With Oint Threolone, Synthomycine or Aqua Cream, for EGFR'I Induced Acneiform Rash
NCT ID: NCT01256437
Last Updated: 2017-05-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
90 participants
INTERVENTIONAL
2011-01-31
2017-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of a Topical Treatment for Actinic Keratosis
NCT01921907
Safety and Tolerability Study of ZEP-3 Cream (0.1% and 1.0%), Administered Topically In Healthy Volunteers
NCT01863160
Phase III Study of Monolaurin Cream Therapy for Patients With Congenital Ichthyosis
NCT00004690
A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities
NCT01787383
Prevention of Drug Rash From Certain Cancer Therapies Using Tretinoin Cream
NCT01349556
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ointment Threolone
Treatment with topical application of combined anti inflammatory and anti bacterial agent.
Threolone ointment
ointment once daily for 1 month
ointment Synthomycine
ointment once daily for 1 month
Aqua cream
ointment once daily for 1 month
ointment Synthomycine
ointment once daily for 1 month
ointment Synthomycine
ointment once daily for 1 month
Aqua cream
ointment once daily for 1 month
Aqua cream
Aqua cream
ointment once daily for 1 month
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Threolone ointment
ointment once daily for 1 month
ointment Synthomycine
ointment once daily for 1 month
Aqua cream
ointment once daily for 1 month
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Known hypersensitivity to ointment Synthomycine or to Threolone.
* Patients presented with cutaneous rash during the 2 weeks prior to study initiation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rabin Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
iris amitay
Iris Amitay-Laish, MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Davidoff Center, Rabin Medical Center, Beilinson
Petah Tikva, Israel, Israel
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lee JE, Lee SJ, Lee HJ, Lee JH, Lee KH. Severe acneiform eruption induced by cetuximab (Erbitux). Yonsei Med J. 2008 Oct 31;49(5):851-2. doi: 10.3349/ymj.2008.49.5.851.
Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010 Mar 10;28(8):1351-7. doi: 10.1200/JCO.2008.21.7828. Epub 2010 Feb 8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
6046
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.